“In a single-center single-arm phase-2 trial of 20 patients with advanced fumarate-hydratase-deficient renal-cell carcinoma, first-line tislelizumab plus lenvatinib produced a 95% objective response rate and 100% disease-control rate, while grade 3-or-higher treatment-related adverse events occurred in 45%.”

0.8581 under ledger-default@0.3.0 at snapshot 27745.

What was asked, and where it stands. Provisional until audited.

Review 50% done · 25% counted in review coverage · 25% by the claims' own author only (1 claim, 4 checks)

Share:

Checked in Galedra: score 0.86, mostly supported · not yet reviewed by anyone else “In a single-center single-arm phase-2 trial of 20 patients with advanced fumarate-hydratase-deficient renal-cell carcinoma, first-line tislelizumab plus lenvatinib produced a 95% objective response…” https://galedra.org/investigations/01a0eab6-87fd-7f0c-9808-fcaa53408273

“In a single-center single-arm phase-2 trial of 20 patients with advanced fumarate-hydratase-deficient renal-cell carcinoma, first-line tislelizumab plus lenvatinib produced a 95% objective response rate and 100% disease-control rate, while grade 3-or-higher treatment-related adverse events occurred in 45%.”

Supported · 0.8581 under ledger-default@0.3.0 at snapshot 27745 · review checks 1 of 4 · provisional until audited.

2 of 4 review checks done · 1 counted · 1 by the author only

See the evidence · Claim card